Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 10:08:09 11/03/2026 pm IST			5-day change	1st Jan Change
40.02 ^EUR	+0.98%		+6.99%	+8.12%

11/03	Bayer takes its battle on pesticide liability to Kansas	RE
11/03	CBOT Trends-Wheat up 7-8 cents, corn up 6-7, soybeans up 17-20	RE

Goldman raises Bayer to 'Buy' - target high at 33 euros

Published on 06/05/2025 at 12:11 pm IST - Modified on 06/05/2025 at 12:50 pm IST

dpa-AFX - Translated by Marketscreener - See original

BAYER AG

+0.98%

NEW YORK (dpa-AFX Broker) - US investment bank Goldman Sachs has raised its target price for Bayer shares from €29.10 to €33 and upgraded the stock from "neutral" to "buy." James Quigley sees a favorable risk/reward ratio for the Leverkusen-based company in the second half of 2025. This also applies in view of further news on the legal disputes, he wrote in his buy recommendation published on Thursday. /ag/tih

Publication of the original study: June 5, 2025 / 5:00 a.m. / BST

Initial distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

-----------------------

dpa-AFX Broker – trader news from dpa-AFX

-----------------------

Latest news about Bayer AG

11/03	Bayer takes its battle on pesticide liability to Kansas	RE
11/03	CBOT Trends-Wheat up 7-8 cents, corn up 6-7, soybeans up 17-20	RE
11/03	BAYER AG : Receives a Buy rating from Barclays	ZD
11/03	Bayer to Continue 'Multi-pronged Approach' to Contain Litigation Risks in US Agriculture Sector	MT
11/03	Bayer-backed Bill to Safeguard Pesticide Makers for Cancer Lawsuits Under Scrutiny in Kansas	MT
11/03	Bayer takes its battle on pesticide liability to Kansas	RE
10/03	Zapata Quantum, Inc. Announces Appointments to its Growth Advisory Board	CI
09/03	BAYER AG : Receives a Buy rating from JP Morgan	ZD
09/03	BAYER AG : Gets a Buy rating from Barclays	ZD
06/03	Mwb Sees 'Better Visibility' for Bayer into 2026; Price Target Up	MT
06/03	Berenberg: US Supreme Court Ruling 'Still Important' for Bayer's Glyphosate Payouts; Hold Rating Kept	MT
06/03	In the $7.25 billion Roundup settlement, opting out comes at a price	RE
05/03	Illumina, Inc. and Nashville Biosciences, LLC Announce New Proteomics Data Offering and Expansion of Alliance for Genomic Discovery Dataset	CI
05/03	BAYER AG : Deutsche Bank reiterates its Neutral rating	ZD
05/03	BAYER AG : Buy rating from Goldman Sachs	ZD

Chart Bayer AG

Duration

Period

BAYN: Dynamic Chart

Company Profile

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (47.5%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (39.1%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.7%). Net sales are distributed geographically as follows: Germany (5.7%), Switzerland (1%), Europe-Middle East-Africa (22.9%), United States (33.1%), North America (3.6%), China (7.6%), Asia-Pacific (8.9%), Brazil (9.6%), and Latin America (7.6%).

Employees

87,280

Sector

Pharmaceuticals

Calendar

27/04 - Ex-dividend date - 0.11 EUR

More about the company